aminolevulinic acid has been researched along with Dermatitis Medicamentosa in 13 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017) |
| " The objective of this study was to evaluate the impact of antihistamines upon adverse effects following ALA-PDT." | 2.84 | A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. ( Goldman, MP; Jones, IT; Vanaman Wilson, MJ; Wu, DC, 2017) |
| "Severe acne vulgaris has limited therapeutic options." | 2.82 | Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. ( Bukhalo, M; Eichenfield, LF; Jarratt, M; Pariser, DM; Waterman, G, 2016) |
| "Pain was low and manageable by briefly pausing illumination." | 2.82 | Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. ( Bukhalo, M; Eichenfield, LF; Jarratt, M; Pariser, DM; Waterman, G, 2016) |
| "Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)." | 1.46 | Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vanaman Wilson, MJ | 1 |
| Jones, IT | 1 |
| Wu, DC | 1 |
| Goldman, MP | 1 |
| Togsverd-Bo, K | 1 |
| Halldin, C | 1 |
| Sandberg, C | 1 |
| Gonzalez, H | 1 |
| Wennberg, AM | 1 |
| Sørensen, SS | 1 |
| Wulf, HC | 4 |
| Haedersdal, M | 1 |
| Borgia, F | 1 |
| Saitta, C | 1 |
| Vaccaro, M | 1 |
| Franzè, MS | 1 |
| Lentini, M | 1 |
| Cannavò, SP | 1 |
| Neal, DE | 1 |
| Smith, RJ | 1 |
| Aberbigbe, O | 1 |
| Etzkorn, JR | 1 |
| Brooke, RC | 1 |
| Sidhu, M | 1 |
| Sinha, A | 1 |
| Watson, RE | 1 |
| Friedmann, PS | 1 |
| Clough, GF | 1 |
| Rhodes, LE | 1 |
| Petersen, B | 1 |
| Wiegell, SR | 2 |
| Pariser, DM | 1 |
| Eichenfield, LF | 1 |
| Bukhalo, M | 1 |
| Waterman, G | 1 |
| Jarratt, M | 1 |
| Kluger, N | 1 |
| Jeskanen, L | 1 |
| Höök-Nikanne, J | 1 |
| Nissen, CV | 1 |
| Heerfordt, IM | 1 |
| Mikkelsen, CS | 1 |
| Al Malki, A | 1 |
| Marguery, MC | 1 |
| Giordano-Labadie, F | 1 |
| Konstantinou, MP | 1 |
| Mokeddem, L | 1 |
| Lamant, L | 1 |
| Paul, C | 1 |
| Maza, A | 1 |
| Mazereeuw-Hautier, J | 1 |
| Alloo, A | 1 |
| Garibyan, L | 1 |
| LeBoeuf, N | 1 |
| Lin, G | 1 |
| Werchniak, A | 1 |
| Hodi, FS | 1 |
| Flaherty, KT | 1 |
| Lawrence, DP | 1 |
| Lin, JY | 1 |
| Philipsen, P | 1 |
| Ladner, DP | 1 |
| Klein, SD | 1 |
| Steiner, RA | 1 |
| Walt, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy[NCT02451579] | 20 participants (Anticipated) | Interventional | 2015-02-28 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation[NCT01474551] | Phase 2 | 2 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 will be used to determine treatment response. In order to be considered evaluable for response, a patient must have completed at least 1 cycle of therapy. Patients who do not complete a cycle of therapy can be replaced. (NCT01474551)
Timeframe: 2 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stable Disease | Complete Response | Partial Response | Progression of Disease | |
| Vemurafenib | 1 | 0 | 0 | 0 |
7 trials available for aminolevulinic acid and Dermatitis Medicamentosa
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Cetirizine; Double-Blind Method; Drug Eruption | 2017 |
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Topics: Aged; Aminolevulinic Acid; Drug Eruptions; Facial Dermatoses; Female; Hand Dermatoses; Humans; Imiqu | 2018 |
Prostaglandin E2 and nitric oxide mediate the acute inflammatory (erythemal) response to topical 5-aminolaevulinic acid photodynamic therapy in human skin.
Topics: Administration, Cutaneous; Adult; Aged; Aminolevulinic Acid; Cyclooxygenase Inhibitors; Dinoprostone | 2013 |
Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
Topics: Aminolevulinic Acid; Drug Eruptions; Erythema; Female; Fluorescence; Humans; Keratosis, Actinic; Mal | 2014 |
Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Aminolevulinic Acid; Child; Double-Blin | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Dru | 2012 |
6 other studies available for aminolevulinic acid and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver | 2017 |
Cells to Surgery Quiz: July 2018.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Diseas | 2018 |
Photodynamic therapy-triggered bullous pemphigoid.
Topics: Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Drug Eruptions; Facial Neoplasms; Humans; M | 2017 |
Systemic allergic contact dermatitis caused by methyl aminolaevulinate in a patient with keratosis-ichthyosis-deafness syndrome.
Topics: Aminolevulinic Acid; Cellulitis; Deafness; Drug Eruptions; Female; Humans; Ichthyosis; Keratitis; Mi | 2017 |
Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy.
Topics: Adult; Aminolevulinic Acid; Dermatitis, Allergic Contact; Drug Eruptions; Female; Humans; Patch Test | 2004 |
Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant.
Topics: Aminolevulinic Acid; Drug Eruptions; Drug Synergism; Female; Humans; Hypericum; Middle Aged; Photose | 2001 |